[Recurrence risk factors of platinum-sensitive epithelial ovarian cancer]
- PMID: 15946495
[Recurrence risk factors of platinum-sensitive epithelial ovarian cancer]
Abstract
Background & objective: The prognosis of platinum-sensitive ovarian cancer patients was better than that of chemoresistant ones. However, platinum-sensitive ovarian cancer patients still have a high recurrence rate, which affects their prognosis. This study was designed to analyze clinical features and recurrence risk factors of platinum-sensitive epithelial ovarian cancer.
Methods: Factors that might relate to recurrence of 90 platinum-sensitive epithelial ovarian cancer patients, admitted in Cancer Center of Sun Yat-sen University from 1993 to 1999, with complete remission of more than 6 months, were assessed. Univariate analysis was performed using Chi(2) test; while multivariate analysis was carried out using Cox proportional hazard model.
Results: Among the 90 patients, 36(40.0%) relapsed with the median recurrence-free interval of 20 months. Pelvic cavity (18/36, 50.0%) was the most frequently involved. The 3-and 5-year survival rates of all patients were 79.6% and 69.5%; while those of the recurrent ones were 62.3% and 39.6%. Univariate analysis showed that the early FIGO stage group, mucinous type group, and no neoadjuvant chemotherapy group had lower recurrence rates than advanced FIGO stage group, non-mucinous type group, and neoadjuvant chemotherapy group, respectively (P=0.001, P=0.002, and P=0.025). Cox multivariate analysis showed that only FIGO stage was the independent risk factor of recurrence of ovarian cancer (risk ratio=1.771, P=0.003). There was no significant difference in recurrence rate between CBP and other postoperative chemotherapy regimen groups. More cycles of chemotherapy could not reduce the recurrence rate.
Conclusion: Since FIGO stage is an independent recurrence risk factor of platinum-sensitive epithelial ovarian cancer patients, early diagnosis is the key point to decrease the recurrence rate.
Similar articles
-
[Analysis of risk factors for epithelial ovarian cancer recurrence].Ai Zheng. 2003 Nov;22(11):1197-200. Ai Zheng. 2003. PMID: 14613652 Chinese.
-
[Comparison of therapeutic efficacy between TP regimen and CBP regimen on epithelial ovarian cancer after optimal cytoreductive operation].Ai Zheng. 2007 Apr;26(4):431-4. Ai Zheng. 2007. PMID: 17430668 Clinical Trial. Chinese.
-
[Expression and clinical significance of uPA and PAI-1 in epithelial ovarian cancer].Ai Zheng. 2007 Mar;26(3):312-7. Ai Zheng. 2007. PMID: 17355798 Chinese.
-
Estrogen and progesterone receptor status as prognostic indicators in patients with optimally cytoreduced stage IIIc serous cystadenocarcinoma of the ovary.Gynecol Oncol. 1996 Mar;60(3):424-7. doi: 10.1006/gyno.1996.0067. Gynecol Oncol. 1996. PMID: 8774651 Review.
-
[Epithelial ovarian cancer].Ther Umsch. 2007 Jul;64(7):375-80. doi: 10.1024/0040-5930.64.7.375. Ther Umsch. 2007. PMID: 17948754 Review. German.
Cited by
-
Survival outcomes following interval versus primary debulking surgery in advanced epithelial ovarian cancer: A retrospective cohort study in Lagos, Southwest Nigeria.Res Sq [Preprint]. 2024 Jan 5:rs.3.rs-3834135. doi: 10.21203/rs.3.rs-3834135/v1. Res Sq. 2024. PMID: 38260667 Free PMC article. Preprint.
-
Predictors of Survival Outcomes After Primary Treatment of Epithelial Ovarian Cancer in Lagos, Nigeria.JCO Glob Oncol. 2021 Jan;7:89-98. doi: 10.1200/GO.20.00450. JCO Glob Oncol. 2021. PMID: 33449803 Free PMC article.
-
Risk predictors of early recurrence in women with epithelial ovarian cancer in Lagos, Nigeria.Pan Afr Med J. 2020 Aug 12;36:272. doi: 10.11604/pamj.2020.36.272.17827. eCollection 2020. Pan Afr Med J. 2020. PMID: 33088401 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical